Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: KZAP who wrote (49078)	5/31/2000 8:11:00 PM
From: Jim Bishop	Read Replies (2) \| Respond to of 150070

<I'll take it off your hands Jim> At $1.63 right now?

To: KZAP who wrote (49078)	6/1/2000 9:41:00 AM
From: Joe Copia	Read Replies (1) \| Respond to of 150070

bought ATEA on $2.05 dividend news and NMPS see below Astea International Reappoints Founder President and CEO And Announces Dividend HORSHAM, Pa., May 31 /PRNewswire/ -- Astea International Inc. (Nasdaq: ATEA - news)announced that its board of directors has appointed Zack Bergreen to the position of President and Chief Executive Officer, replacing Bruce Rusch who resigned from that position effective today. Mr. Bergreen had been the Company's Chief Executive Officer from its inception in 1988 until August 1999. He will remain as Chairman of the Board of Directors. In addition the Board of Directors approved a one-time cash dividend of $2.05 per share on its common stock. The dividend will be paid on June 30, 2000 to record holders as of June 15, 2000. and NMPS on 100% cancer detection news. Matritech Reports 'Proof of Clinical Concept' For Breast Cancer Blood Test Is Complete All cases of cancer were detected by the NMP66' test NEWTON, Mass., June 1 /PRNewswire/ -- Matritech, Inc. (Nasdaq: NMPS - news), a company specializing in products designed to detect, manage and screen for cancer, today announced that it has completed the 'proof of clinical concept' of its proprietary NMP66 blood test for women with, or at risk of, breast cancer. The NMP66 test is based on the Company's nuclear matrix protein (NMP) technology platform, which correlates levels of NMPs in body fluids to the presence of cancer.......